Product Description
Chlorproguanil has been used in trials studying the treatment of MALARIA. It is a dichloro-derivative of chloroguanide. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Chlorproguanil)
Mechanisms of Action: DHFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Malaria, Falciparum
Phase 3: Malaria, Falciparum|Malaria|Malaria, Vivax
Phase 1: Malaria
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ITCRVG04 | P3 |
Completed |
Malaria |
2007-09-01 |
|
| DIF 35 | P3 |
Terminated |
Malaria |
2007-08-01 |
|
| CDA 714703/005 | P3 |
Completed |
Malaria, Falciparum |
2007-08-01 |
|
| CDA 714703/006 | P3 |
Completed |
Malaria, Falciparum |
2007-05-01 |